Dutch Health Ingredients company Nutrileads has announced the closing of a Series B financing round of €6.5 million. The funding is provided by Icos Capital together with Goeie-Grutten and existing shareholders DSM Venturing, Oost NL, Shift Invest and Thuja. Nutrileads will use the capital to launch its the immune-enhancing ingredient Xtramune and to progress its portfolio of health ingredients.
NutriLeads, one of the startups to pitch at the first edition of F&A Next in 2016, develops innovative natural food ingredients with clinically proven health benefits for application in dietary supplements and functional foods. Its proprietary lead ingredient, XtramuneTM, is a unique carrot-derived fibre supporting immune function and resistance to respiratory infections.
Next level
This series B funding round marks a new phase for the company. Together with global partners in the food and supplement industry, NutriLeads will be driving XtramuneTM towards commercialization in 2021. In addition, two other ingredients from its portfolio, targeting gut health and metabolic health, will be progressed to proof of concept in humans.
Unlocking potential
Ruud Albers, CEO of NutriLeads indicates: “We are very excited about this successful funding round which helps to propel NutriLeads forward. People can strengthen their health with nutrition. It is our ambition to unlock the potential of clinically proven food ingredients and this funding round supports that mission. It is great to see that all our investors are committed to this shared goal.”
Nityen Lal, Managing Director of ICOS Capital Management BV: “Health ingredients are sought-after by food companies and their consumers. NutriLeads has impressed us by its professionalism, the quality of the work done and their network in the industry. We are confident that this is a worthwhile investment both for our LPs as well as for the consumers who will benefit from the health ingredients to be marketed.”
Image: (C) Oost NL
